🇺🇸 FDA
Pipeline program

IL-15-armored CAR-T cells

MM IL-15-Armored CAR-T

Phase 2 mab active

Quick answer

IL-15-armored CAR-T cells for Relapsed/Refractory Multiple Myeloma is a Phase 2 program (mab) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Relapsed/Refractory Multiple Myeloma
Phase
Phase 2
Modality
mab
Status
active

Clinical trials